Mini-TCRs: Truncated T cell receptors to generate T cells from induced pluripotent stem cells.

"Declaration of interests This work was supported by a collaborative research grant from Kirin Holdings. S.-i.T., S.H., K.F., A.K., S.N., and S. Kaneko declare a patent titled “WO2020138371 MODIFIED TCR AND PRODUCTION METHOD THEREFOR” related to this work. S.-i.T., S.H., K.F., S.C., Y.K., A.K., and H.N. are employed by Kirin Holdings Co., Ltd. K.N. and B.W. are an employee and a part-time employee of Shinobi Therapeutics, Inc., respectively. S. Kaneko is a founder, shareholder, and chief scientific officer at Shinobi Therapeutics, Inc., and received research funding from Kirin Holdings Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Shinobi Therapeutics, Inc.; Astellas Co., Ltd.; Terumo Co., Ltd.; and Tosoh Co., Ltd."

"Declaration of interestsThis work was supported by a collaborative research grant from Kirin Holdings. S.-i.T., S.H., K.F., A.K., S.N., and S. Kaneko declare a patent titled “WO2020138371 MODIFIED TCR AND PRODUCTION METHOD THEREFOR” related to this work. S.-i.T., S.H., K.F., S.C., Y.K., A.K., and H.N. are employed by Kirin Holdings Co., Ltd. K.N. and B.W. are an employee and a part-time employee of Shinobi Therapeutics, Inc., respectively. S. Kaneko is a founder, shareholder, and chief scientific officer at Shinobi Therapeutics, Inc., and received research funding from Kirin Holdings Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Shinobi Therapeutics, Inc.; Astellas Co., Ltd.; Terumo Co., Ltd.; and Tosoh Co., Ltd."